Trial Profile
PHASE II CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA WITH A COMBINATON OF BENDAMUSTINE AND OFATUMUMAB.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- 19 Jul 2011 Planned end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 19 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 May 2010 New trial record